


The Litigation of Financial Innovations



Josh Lerner

Harvard University and NBER



This project

- Seeks to understand consequences of patenting of business methods.
- Focuses on litigation of finance patents.
- Key findings:
 - Extraordinary high litigation rates.
 - Especially of patents to individuals, private firms.
 - Driven by third parties.
 - Larger firms are targeted.

What is patentable?


- Criteria under U.S. patent law:
 - Novelty.
 - Utility.
 - Non-obviousness.
 - “Any new and useful process, machine, manufacture, or composition of matter.”
 - Interpretation has varied over time!

Treatment of business methods

- Ambiguity in common law countries:
 - Apparently allowed in *Darcy v. Allin* (U.K. 1602).
 - Excluded in subsequent decisions:
 - *Hotel Security Checking v. Lorraine Co.* (1908) established “business method exception” to patentability in U.S.
 - Contrast with civil law countries.

Treatment of business methods (2)

- While USPTO began issuing awards in 1970s, questions about validity:
 - Only two filed cases prior to 1996 settled before trial.
 - Many financial institutions, service providers relied on trade secrecy.



The *State Street* case

- Signature Financial obtained patent on “hub and spoke” system of mutual fund management in 1993.
- Approached mutual fund custodians to license, with some success.
- Licensing talks with State Street Bank & Trust proved unsuccessful.

The *State Street* case (2)

- State Street sued in 1996 to have patent declared invalid.
- Federal District of Massachusetts made summary judgment in favor of State Street:
 - “Jurisprudential quagmire.”
- Signature appealed to CAFC.

The *State Street* case (3)

- CAFC reversed decision in July 1998:
 - The [district] court relied on the judicially-created, so-called “business method” exception to statutory subject matter. We take this opportunity to lay this ill-conceived exception to rest.
- Supreme Court refused to hear appeal in January 1999.
- Decisions much discussed in trade press.



US007426488B1

(12) **United States Patent**
Gompers et al.

(10) **Patent No.:** **US 7,426,488 B1**
(45) **Date of Patent:** **Sep. 16, 2008**

(54) **PRIVATE EQUITY INVESTMENTS**

(76) Inventors: **Paul A. Gompers**, 156 Mason Ter., Brookline, MA (US) 02446; **Joshua Lerner**, 108 Moulton St., South Hamilton, MA (US) 01982; **Andrew Metrick**, 604 Schiller Ave., Merion Station, PA (US) 19066; **Leslie Ann Jeng**, 32 River St., Cambridge, MA (US) 02139

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1333 days.

(21) Appl. No.: **09/990,893**

(22) Filed: **Nov. 14, 2001**

Related U.S. Application Data

(60) Provisional application No. 60/248,272, filed on Nov. 14, 2000.

(51) **Int. Cl.** *G06Q 40/00* (2006.01)

(52) **U.S. Cl.** *705/36 R; 705/35*

(58) **Field of Classification Search** *705/36 R, 705/35, 45, 30, 33; 707/202, 1, 10*
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,220,500 A * 6 1993 Baird et al. 705 36 R
5,812,987 A * 9 1998 Juskin et al. 705 36 R

OTHER PUBLICATIONS

Madura, Jeff Book "financial Markets and Institutions" second edition, Florida Atlantic University, West Publishing Company, 1992, ISBN: 0-314-87735-5.*

Gompers, Paul A., et al., Risk and Reward in Private Equity Investments: The Challenge of Performance Assessment, The Journal of Private Equity, Winter, 1997.

Lerner, Josh, et al., Yale University Investments Office, Nov. 1997, Harvard Business School, Rev. Sep. 28, 1998, p. 1-25, Harvard Business School Publishing, Boston, MA.

Armstrong, Elissa, Private Equity The New Asset Class, Highlights of the London Business School Report "UK Venture Capital and Private Equity as an Asset Class for Institutional Investors", BVCA, London, England.

Long, Austin M., III, Converting IRRs to Time-Weighted Returns, IQ Markets, Inc., www.iqmarkets.com, Sep. 8, 2000.

Huntsman, Blaine, et al., Investment in New Enterprise: Some Empirical Observations on Risk, Return, and Market Structure, Huntsman and Hoban Investment in New Enterprise, Summer, 1980, p. 44-50.

Gardner, Grant, et al., Private Equity in Asset Allocation, Russell, Sep. 1995, p. 1-10.


(Continued)

Primary Examiner Mary Cheung
Assistant Examiner Kirsten S Apple
(74) *Attorney, Agent, or Firm* Foley Hoag LLP

(57) **ABSTRACT**

In general, in one aspect, the disclosure describes a computer program for analyzing private equity investments. The program includes instructions that access public equity data identifying performance of a set of more than one public equities. The instructions also access private equity data identifying one or more characteristics of different private equity investments. The program analyzes a private equity investment based, at least in part, on the public equity data and the private equity data of other private equity investments.

37 Claims, 6 Drawing Sheets



The *Bilski* case

- Patent application for method of hedging commodities trading:
 - Rejected by Board of Patent Appeals and Inferences.
 - Appealed to CAFC:
 - Rejection upheld in October 2008 in 9-3 decision.
 - “Of course, a claimed process wherein all of the process steps may be performed entirely in the human mind is obviously not tied to any machine and does not transform any article into a different state or thing. As a result, it would not be patent-eligible.”

The *Bilski* case (2)

- Decision appealed to U.S. Supreme Court:
 - Ruling expected imminently.
 - Considerable skepticism about business method patents in oral arguments.
 - Their suggestions:
 - How to choose a jury (Justice Ginsberg), teaching antitrust law without putting students to sleep (Justice Breyer), speed-dating (Justice Sotomayor), horse-whispering (Justice Scalia).

Critique of business method awards

- “Although patents in other areas of technology have brought forth complaints from various quarters, the magnitude of adverse commentary and reportage on business method patents was unprecedented.”
 - Allison and Hunter (2005).
 - “The increased volume of patent applications stemming from this newly patentable subject matter has pushed the patent system into crisis.”
 - Merges (2000).
 - “A new monster called forth from an old statute.”
 - Lessig (2000).

Response

- In 2000, USPTO introduced “Second Pair of Eyes Review.”
 - All patents in class 705 get second review.
- Consequences:
 - Slow-down in awards.
 - Substitution into other classes.
 - Allison and Hunter (2005).

More generally

- Enormous economics literature on design of intellectual property rights:
 - E.g., Scotchmer (2004).
- Substantial works on patents as indicators:
 - Griliches (1990); Jaffe and Trajtenberg (2002).
- But little attention to understanding quality of issued awards:
 - Exceptions include work on oppositions [Hall, et al. (2005)], examiners [Cockburn, Kortum, and Stern (2003)], and patent trends [Kortum and Lerner (1997)].

Second motivation: Financial innovation's importance

- Claims in Miller (1986), Merton (1992).
- Evidence from Tufano (1989):
 - Substantial turnover of securities issued.
- Potential implications for other firms:
 - Easing capital constraints?
 - Reducing cost of capital?
 - But also skeptics.



"I can't sleep. I just got this incredible craving for capital."

Yet little study

- Frame and White (2005) identify 39 empirical studies of financial innovation:
 - Contrast to 1000s on manufacturing innovation.
 - Most focused on “back end”:
 - Diffusion and consequences.
 - Only two papers on origins of innovation.


Likely different dynamics

- Little patent protection until recently.
- Great deal of disclosure due to regulatory, marketing considerations.
- Importance of collaborations.
 - ⇒ Imply that important to examine as a distinct phenomenon.

Part of series

- Lerner (2002):
 - Lots of awards and more coming!
 - Minimal academic role in patenting:
 - Largely due to lack of interest or understanding, rather than subject matter.
 - Little reference to academic research:
 - Apparently due to background of examiners.

Journal and Author	Survey Responses		
	Expert A	Expert B	Expert C
<i>Journal of Finance</i>			
Barberis (2000)	+	++	++
Pástor (2000)	++	++	++
Rajan, Servaes, and Zingales (2000)	--	--	0
Wilner (2000)	--	-	0
<i>Journal of Financial Economics</i>			
Bakshi and Madan (2000)	+	+	++
Bertsimas, Kogan, and Lo (2000)	+	-	++
Gupta and Subrahmanyam (2000)	--	0	++



Part of series (2)

- Lerner (2006):
 - Small firms play as important—even disproportionate—role in financial innovation.
 - Less profitable firms with stronger academic ties innovate more:
 - Consistent with (some) theoretical suggestions.
 - Increase in profitability after innovation.
 - After *State Street*, large firms increasingly dominate innovations:
 - Fundamental change?

The sample: Identifying finance patents

- Patents are sorted into >100,000 subclasses.
- Relevant subclasses:
 - 705/4.
 - 705/35 through 705/45.
 - 902/1 through 902/41.

The sample: Identifying patent litigation

- Employ Derwent on-line database.
- Based on reports to USPTO by courts.
- Incomplete due to:
 - Non-reporting to USPTO.
 - Lawsuits not yet filed.
- Supplement missing data

The sample: Patentee characteristics


- Sort into awards to public and private firms, individuals, and others.
- Obtain financial, employment data from:
 - Compustat.
 - WorldScope.
 - Nation and industry directories.
 - Less data (if any) for private firms.

The sample: Patent characteristics

- Download from HBS patent database web site:
 - Applicant and assignee name.
 - Application and award dates.
 - Patent classification.
 - Prior art cited and subsequent citations (through July 2006).

Table 1, Panel A

<u>Panel A: Patent Awards</u>	<i>Mean</i>	<i>Std. Dev.</i>	<i>Min.</i>	<i>Max.</i>
Award year	1994.7	7.3	1976	2003
Application year	1992.1	7.1	1969	2002
Claims made	20.9	20.9	1	375
Citations made	13.3	17.6	0	243
Citations made per claim	1.2	3.1	0	121.5
Citations received through July 2006	24.0	33.2	0	407
Citations received through July 2006 per claim	2.3	6.0	0	129
Self-citations made	0.6	2.1	0	60
Self-citations received through July 2006	0.4	1.0	0	15
Generality	0.44	0.25	0.07	1
Originality	0.53	0.27	0.06	1
Sales of assignee in award year (billions of 2003\$s)	24.9	37.8	0	467
Employment of assignee in award year (000s)	86.0	113.3	0.005	891
Assignee is a U.S.-based individual	16.0%			
Assignee is a non-U.S.-based individual	2.3%			
Assignee is a U.S.-based public corporation	32.5%			
Assignee is a non-U.S.-based public corporation	16.2%			
Assignee is a U.S.-based private firm	24.9%			
Assignee is a non-U.S.-based private firm	7.7%			
Nationality of assignee (if non-U.S.):				
Japanese	57.6%			
British	8.5%			
French	6.5%			
German	6.3%			
Lawsuits involving patent through end of 2005	0.08	0.59	0	15





Summary statistics

- Back-end loaded sample.
- Heavily cited (4x general level).
- Under-representation of foreign firms (one-half level).
- Little government or university patenting.

Table 1, Panel B

<u>Panel B: Lawsuits</u>	<i>Mean</i>	<i>Std. Dev.</i>	<i>Min.</i>	<i>Max.</i>
Number of financial patents in suit	1.32	1	1	7
Patents awarded to plaintiff?	5.90%			
Patents assigned to plaintiff?	32.60%			
Patents awarded to defendant?	1.10%			
Patents assigned to defendant?	6.40%			






Lawsuit features

- Most cases around only one patent.
- Only 46% of cases involve inventor or assignee as plaintiff or defendant:
 - Hints at importance of individual inventors here.

Most frequently represented firms

<i>Innovators</i>	<i>Patentees</i>	<i>Litigators</i>	<i>Defendants</i>
Merrill Lynch	Hitachi	Panip, LLC	American Express
Citigroup	IBM	Divine, Inc.	Citigroup
American Express	NCR	Source, Inc.	Chicago Board of Trade
Citicorp	Citigroup	Meridian Enterprises	New York Mercantile Exchange
McGraw-Hill	Fujitsu	Travelers Express Co.	JP Morgan Chase
Charles Schwab	AT&T	Allcare Health Management	



Most frequent parties


- Innovators, defendants dominated by major financial institutions.
- IT consultants play a much more important role in financial patenting.
- Plaintiffs dominated by holding firms.
- Defendants appear to have deep pockets.

Adjustments

- Use Lanjouw-Schankerman [2001, 2003] factors to adjust for:
 - Non-reporting to USPTO.
 - Truncation due to litigation over patent life.
- No adjustment for understating due to reporting delays.


Additional adjustments

- Patent count:
 - L&S employed only one patent per suit.
 - In actuality, approximately 1.3 per suit.
 - Researched pre-1990 cases.
- Suit consolidation:
 - Derwent frequently has multiple entries for lawsuits, sometimes with slightly different docket numbers.
 - Consolidation of these cases.
 - Impact hard to measure exactly, but likely to be 10%-20% reduction.
 - No adjustment for evident reporting delay.



Comparing to L&S

- Dramatically higher rates of litigation:
 - 10.7 cases per 1000 in overall data.
 - 293.5-429.3 per thousand here.
 - 27-39 times greater rate here!
 - Highest category, drugs, is 20.1.
- Far more litigation by third parties:
 - 56% in sample not litigated by awardee or assignee.
 - In L&S, only 31%.
- Like them, no clear time trend.



Cross-sectional differences

- Also look across population of business method patents:
 - Whose awards are being litigated?
 - What seem to be key drivers of litigation?
 - What can we infer from these patterns?

Adjusted lawsuits by firm type

<i>Firm type in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>
Publicly Traded	114.5
Privately Held	396.6
Individual	591.7

Adjusted lawsuits by firm location


<i>Assignee nation in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>
United States	382.8
Japan	29.9
Other	61.0

Adjusted lawsuits by employees

<i>Employees in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>	<i>Employees in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>
0-200	1153.0	50,001-200,000	47.1
201-1000	313.1	>200,000	0.0
1001-50,000	80.3		

Adjusted lawsuits by sales (\$M)

<i>Revenues in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>	<i>Revenues in award year</i>	<i>Adjusted lawsuits/ 1000 patents</i>
0-10	790.9	1000.1-10,000	84.5
10.1-100	681.5	10,000.1-50,000	45.1
100.1-1000	74.7	>50,000	0.0



Litigation patterns

- Unlike overall, corporate financial patents less likely to be litigated.
- U.S. patents 9x more likely to be litigated.
- Dramatic fall-off in litigation with firm size (overall, no patterns).

Table 5

	<u>Domestic</u>		<u>Foreign</u>	
	<i>Litigated</i>	<i>Not Litigated</i>	<i>Litigated</i>	<i>Not Litigated</i>
Claims	31.00	22.73 ***	24.83	14.40 *
Forward citations/year	4.04	2.40 ***	4.07	1.40 ***
Backward citations	19.39	14.78 **	9.83	8.24
Forward cites/year/claim	0.28	0.20 *	0.21	0.16
Backward cites/claim	1.77	1.18 *	0.61	0.96

Comparing patents

- Litigated patents:
 - Have more claims.
 - Are more cited.
 - But, unlike overall, magnitude of differences much small when examine cites per claim.
 - Have more backward cites:
 - Opposite to overall pattern.

Regression analyses

- Unit of analysis is each patent in sample.
- Dependent variables:
 - Was patent litigated?
 - What was the litigation count?
- Independent variables follow specification in Lanjouw-Schankerman [2001]:
 - Award year fixed effects.
- Also examine predicted effects.


Table 6

	<i>Dependent variable: Was patent litigated?</i>		<i>Dependent variable: Number of lawsuits involving patent</i>			
	<u>Probit</u>	<u>Poisson</u>	<u>Negative Binomial</u>			
	(1)	(2)	(3)	(4)	(5)	(6)
Logarithm of number of claims in patent	0.55 [0.07]***	1.06 [0.10]***	1.13 [0.18]***	0.98 [0.18]***	0.81 [0.18]***	0.85 [0.18]***
Log of forward citations per claim	0.35 [0.08]***	0.67 [0.12]***	0.96 [0.25]***	0.84 [0.24]***	0.7 [0.24]***	0.78 [0.24]***
Log of backward citations per claim	0.55 [0.11]***	0.89 [0.15]***	1.05 [0.30]***	0.92 [0.29]***	0.7 [0.28]**	0.71 [0.29]**
Was assignee a public corporation?				-1.09 [0.27]***	-0.02 [0.36]	0.09 [0.44]
Was assignee an individual?				0.43 [0.28]	0.34 [0.28]	0.28 [0.28]
Was assignee based in the United States?				1.31 [0.39]***	1.39 [0.40]***	1.25 [0.39]***
Log of employment in year of issue (000s)					-0.57 [0.12]***	
Log of sales in year of issue (millions of 2003 \$s)						-0.25 [0.07]***
Year of issue dummy variables	Y	Y	Y	Y	Y	Y
Zero or missing data dummy variables	Y	Y	Y	Y	Y	Y
Controls for self-citation rate	Y	Y	Y	Y	Y	Y
p-Value, χ^2 -test	0.00	0.00	0.00	0.00	0.00	0.00
Pseudo R2	0.10	0.13	0.07	0.11	0.12	0.13
Observations	2757	2941	2941	2941	2941	2941

Table 7

	At means	+1 Standard Deviation in Log Claims	+2 Standard Deviations in Log Claims	+1 Standard Deviation in Log Forward Citations per Claim	+2 Standard Deviations in Log Forward Citations per Claim	+1 Standard Deviation in Log Backward Citations per Claim	+2 Standard Deviations in Log Backward Citations per Claim
Probability of Litigation (regression #1 in Table 6)	3.22%	8.45%	18.37%	5.57%	9.08%	5.71%	9.49%
Count of Lawsuits (#3)	0.024	0.064	0.170	0.049	0.099	0.040	0.067
Count of Lawsuits (#4)	0.014	0.033	0.076	0.026	0.048	0.022	0.035
Count of Lawsuits (#5)	0.005	0.010	0.021	0.009	0.014	0.007	0.010

	At means	Patent Holder is a Public Corporation	Patent Holder is an Individual	Patent Holder is from the United States	+1 Standard Deviation in Log Employment	+2 Standard Deviations in Log Employment
Probability of Litigation (regression #1 in Table 6)	3.22%	-	-	-	-	-
Count of Lawsuits (#3)	0.024	-	-	-	-	-
Count of Lawsuits (#4)	0.014	0.005	0.021	0.052	-	-
Count of Lawsuits (#5)	0.005	0.005	0.007	0.020	0.002	0.000



Key findings

- More litigation is associated with:
 - More claims.
 - More forward citations.
 - More backward citations:
 - Public corporations.
 - U.S.-based firms:
 - Effect driven by individuals and private concerns.

Table 9

	<i>Dependent variable: Number of lawsuits involving firm</i>		
	Negative Binomial		
	Entire Sample (1)	U.S.-Based Firms Only (2)	1999 and After Observations Only (3)
Log years firm has been publicly traded	0.18 [0.25]	0.43 [0.28]	0.30 [0.26]
Log of firm's assets	0.46 [0.14]***	0.36 [0.13]***	0.44 [0.14]***
Profit margin	-0.13 [0.39]	0.04 [0.55]	-0.07 [0.41]
Leverage	-1.62 [1.14]	-1.67 [1.35]	-2.04 [1.09]*
Innovations by firm	0.52 [0.40]	0.38 [0.34]	0.20 [0.27]
Academic connectedness	-0.76 [1.02]	-1.39 [2.80]	-0.61 [0.46]
Other innovations in ZIP code	-0.27 [0.24]	-0.17 [0.23]	0.01 [0.21]
Industry controls	Y	Y	Y
Nationality of patentee dummy variables	Y	N	Y
p-Value, χ^2 -test	0.000	0.000	0.000
Observations	15937	15034	5472

Who gets sued?

- Scale: Bigger is more likely to be sued:
 - If litigation more costly to them than other (reputational or collateral damage), more likely to be targeted.
 - Theory of sham litigation.
- Many other things don't matter:
 - Innovation doesn't matter.
 - Location doesn't matter.

Robustness checks


- Two-stage regression to control for zero observations.
- Using total litigation filings, adjusted lawsuit count as dependent variable.
- Controlling for application year as well.
- Controlling for patent originality and generality:
 - Measures had no power.
- Additional financial data.
- Firm fixed effects.

Interpreting the results

- Key findings:
 - Much more frequent litigation of financial patents.
 - Typically those awarded to individuals and smaller, private entities.
 - Patents with more claims and citations more frequently litigated.
 - Large firms disproportionately targeted.


Interpreting the results (2)

- Consistent with theoretical models of suit and settlement:
 - High-stake disputes should lead to more litigation.
 - If accept claim that larger firms have more costs of litigation:
 - Patterns of lawsuit initiation and targets are consistent.
 - Consistent with models of strategic exploitation of weak patents:
 - Farrell and Shapiro [2008]; Henkel and Reitzig [2007].
 - Suggests broader social costs.



Open questions

- How does litigation impact innovation in financial services?
 - What kind of distortions do weak patents introduce really?
 - How has changing intellectual property environment matter?



Josh Lerner
Rock Center for Entrepreneurship
Harvard Business School
Boston, MA 02163
617-495-6065

josh @ hbs.edu
www.people.hbs.edu/jlerner